High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: Retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation

Volumn 36, Issue 1, 2005, Pages 25-31

  Bengala, Carmelo ^a   Guarneri, V ^a   Ledermann, J ^b   Rosti, G ^c   Wandt, H ^d   Lotz, J P ^e   Cure, J H ^f   Orlandini, C ^g   Ferrante, P ^c   Conte, P F ^a   Demirer, T ^h  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Civic Hospital   (Italy)

^d KLINIKUM NÜRNBERG   (Germany)

^e HÔPITAL TENON   (France)

^f Centre Jean Pierrin   (France)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h ANKARA UNIVERSITY   (Turkey)

Author keywords

Complete remission; Haemopoietic growth factors; High dose consolidation chemotherapy; Ovarian cancer

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 21744459117     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705007     Document Type: Article

References (30)

1. Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 2000; 27 (Suppl. 7): 47-49.
2. Conte PF, Cianci C, Gadducci A. Update in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 1999; 32: 49-58.
3. Bruzzone M, Repetto L, Chiara S et al. Chemotherapy vs radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 1990; 38: 392-395.
4. 32p) vs observation after negative second-look laparoptomy for stage III ovarian carcinoma: a randomised trial of the gynaecologic oncology group. J Clin Oncol 2003; 21: 2849-2855.
5. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 vs 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
6. Pignata S, De Placido S, Scambia G et al. Topotecan vs nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1 (Multicenter Italian Trials in Ovarian Cancer) study. Proc Am Soc Clin Oncol 2003; 22: 446 (Abstr).
7. Pfisterer J, Lortholary A, Kimmig R et al. Paclitaxel/carboplatin (TC) vs Paclitaxel/carboplatin followed by topotecan (TC-Top) in first line treatment of ovarian cancer FIGO stages IIb-IV Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 2003; 22: 446 (abstr).
8. Barakat B, Sabbatini P, Bhaskaran D et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002; 20: 694-698.
9. Bruzzone M, Rubagotti A, Gadducci A et al. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer with minimal residual disease at second-look: a prospective randomised trial of 111 patients. Gynecol Oncol 1997; 65: 499-505.
10. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
11. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
12. Gadducci A, Carnino F, Chiara S et al. Intraperitoneal vs intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157-162.
13. Armstrong DK, Bundy BN, Baergen R et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 2002; 21: 201a (Abstr).
14. Lotz J-P, Bouleuc C, Andrè T et al. Tandem high-dose chemotherapy with ifosfamide, carboplatin and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 1996; 77: 2550-2559.
15. Salerno MG, Ferrandina G, Greggi S et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 2001; 27: 1017-1025.
16. Schilder RJ, Brady MF, Spriggs D et al. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 3-8.
17. Bertucci F, Viens P, Delpero JR et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant 2000; 26: 61-67.
18. Curè H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2004; 23 Abstr. 5006).
19. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-1317.
20. Ledermann JA, Herd R, Maraninchi D et al. High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2001; 12: 693-699.
21. Donato ML, Aleman A, Champlin RE et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004; 33: 1219-1224.
22. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin vs no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003; 13 (Suppl. 2): 196-203.
23. Brun J-L, Feyler A, Chene G et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21-27.
24. Chi DS, Liao JB, Leon LF et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82: 532-537.
25. Heintz APM, Odicino F, Maissonneuve P et al. Carcinoma of the ovary. In: FIGO Annual Report on the results of treatment in Gynecological Cancer. J Epidemol Biostat 2001; 6: 107-138.
26. Norton L, Day R. Potential innovations in scheduling of cancer chemotherapy. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. Lippincott: Philadelphia, PA, 1991, pp 57-72.
27. Aghajanian C, Fennelly D, Shapiro F et al. Phase II study of 'dose dense' high-dose chemotherapy treatment with peripheral blood progenitor cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-1860.
28. Wandt H, Birkmann J, Denzel T et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763-770.
29. Pierelli L, Perillo A, Ferrnadina G et al. The role of the growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomised comparison of G-CSF and GM-CSF. Transfusion 2001; 41: 1577-1585.
30. Fattorossi A, Battaglia A, Pierelli L et al. Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T-cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother 2001; 49: 641-648.